Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295189 | 1.00 | TAAR1 (0.46) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295193 | 1.00 | TAAR1 (0.46) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295272 | 0.86 | TAAR1 (0.53) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295265 | 0.86 | TAAR1 (0.53) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295269 | 0.86 | TAAR1 (0.53) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1296032 | 0.85 | TAAR1 (0.51) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1296036 | 0.85 | TAAR1 (0.51) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1296034 | 0.85 | TAAR1 (0.51) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295381 | 0.85 | TAAR1 (0.51) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1295377 | 0.85 | TAAR1 (0.51) | TAAR1IDO1AGXTCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | VCAM1, AOC3, AOC2 | TAAR1 260/4885IDO1 447/4885AGXT 2992/4885 |
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | TAAR1 260/4885IDO1 447/4885AGXT 2992/4885 |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | TAAR1 260/4885IDO1 447/4885AGXT 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.